Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kamada Ltd (KMDA)

Kamada Ltd (KMDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 281,623
  • Shares Outstanding, K 57,474
  • Annual Sales, $ 142,520 K
  • Annual Income, $ 8,280 K
  • 60-Month Beta 1.04
  • Price/Sales 2.06
  • Price/Cash Flow 12.05
  • Price/Book 1.21
Trade KMDA with:

Options Overview Details

View History
  • Implied Volatility 126.92% ( -53.17%)
  • Historical Volatility 38.10%
  • IV Percentile 85%
  • IV Rank 58.35%
  • IV High 213.87% on 08/16/23
  • IV Low 5.11% on 08/14/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 2.10
  • Today's Open Interest 3,727
  • Open Int (30-Day) 3,717

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.06
  • Number of Estimates 2
  • High Estimate 0.07
  • Low Estimate 0.05
  • Prior Year 0.04
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.90 +3.67%
on 04/16/24
5.95 -14.62%
on 03/19/24
-0.52 (-9.29%)
since 03/15/24
3-Month
4.90 +3.67%
on 04/16/24
6.53 -22.19%
on 03/05/24
-0.53 (-9.45%)
since 01/17/24
52-Week
4.08 +24.51%
on 10/31/23
6.53 -22.19%
on 03/05/24
+0.41 (+8.78%)
since 04/17/23

Most Recent Stories

More News
Kamada: Q4 Earnings Snapshot

Kamada: Q4 Earnings Snapshot

KMDA : 5.08 (+3.67%)
Kamada: Q3 Earnings Snapshot

Kamada: Q3 Earnings Snapshot

KMDA : 5.08 (+3.67%)
Kamada: Q2 Earnings Snapshot

Kamada: Q2 Earnings Snapshot

KMDA : 5.08 (+3.67%)
Kamada: Q1 Earnings Snapshot

Kamada: Q1 Earnings Snapshot

KMDA : 5.08 (+3.67%)
Kamada: Q4 Earnings Snapshot

Kamada: Q4 Earnings Snapshot

KMDA : 5.08 (+3.67%)
Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why

Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.

SNY : 46.11 (+0.68%)
JAZZ : 107.10 (-1.65%)
KMDA : 5.08 (+3.67%)
ZYME : 8.85 (-0.90%)
Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day

Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.

MLAB : 101.14 (-1.33%)
EGO : 14.96 (-0.66%)
ADAP : 0.9870 (-4.17%)
KMDA : 5.08 (+3.67%)
ZYME : 8.85 (-0.90%)
Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive

One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.

REGN : 901.19 (+0.79%)
SNY : 46.11 (+0.68%)
KMDA : 5.08 (+3.67%)
SNDX : 20.74 (-2.54%)
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

ADAP : 0.9870 (-4.17%)
KMDA : 5.08 (+3.67%)
ZYME : 8.85 (-0.90%)
Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer

Merck (MRK) partners with Kelun-Biotech to develop seven antibody-drug conjugates targeting cancer indications. Merck will have an exclusive license to develop and commercialize these candidates.

SNY : 46.11 (+0.68%)
AZN : 68.53 (+0.39%)
MRK : 125.37 (+0.25%)
KMDA : 5.08 (+3.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona,...

See More

Key Turning Points

3rd Resistance Point 5.58
2nd Resistance Point 5.43
1st Resistance Point 5.25
Last Price 5.08
1st Support Level 4.92
2nd Support Level 4.77
3rd Support Level 4.60

See More

52-Week High 6.53
Fibonacci 61.8% 5.59
Fibonacci 50% 5.30
Last Price 5.08
Fibonacci 38.2% 5.02
52-Week Low 4.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar